MedTrace Logo

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

NCT05044091 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-09-14

No results posted yet for this study

Summary

Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer. However, the proportion of HRD positive in real world and relationship of HRD status with PARPi in Chinese ovarian cancer patients remains unknown.

Conditions

Interventions

DRUG

PARP inhibitor

Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions

Sponsors & Collaborators

  • Xiaoxiang Chen

    lead OTHER

Principal Investigators

  • Xiaoxiang Chen, MD,PhD · Jiangsu Cancer Institute & Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2022-09-30
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05044091 on ClinicalTrials.gov